New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 21, 2014
07:55 EDTXYLXylem weakness creates buying opportunity, says Oppenheimer
Oppenheimer believes that the recent weakness in Xylem was caused by the company's statement in the middle of Q2 that sales were tracking at the low end of a 1%-3% increase. However, the firm predicts that the company's Q2 results will be boosted by efficiency gains, and it thinks that the results will be in-line and solid. The firm keeps an Outperform rating on the shares.
News For XYL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 24, 2015
08:04 EDTXYLXylem sees FY15 adjusted EPS $1.82-$1.87, consensus $1.84
Sees FY15 revenue approx. $3.7B, consensus $3.66B. On an organic basis, Xylem expects to generate revenue growth of approximately one to two percent. Full-year 2015 adjusted operating income is expected to be in the range of $470 million to $483 million. Excluding the projected unfavorable impact of foreign exchange translation, Xylem's adjusted earnings per share growth expectations are in the range of four to seven percent over the comparable full-year 2014 results. The Company's outlook for projected restructuring and realignment costs of $20 million for the year is unchanged. "Xylem has a powerful arsenal to fuel our growth and create value for our shareholders," said CEO Patrick Decker. "First, the combination of improving end-market conditions and diligent execution will enable us to deliver faster than market growth. Second, we expect to further expand operating margins by more than 300 basis points over the next five years through focused business simplification and continuous improvement initiatives. And finally, we plan to execute a balanced capital deployment strategy. With strong cash flow and a solid capital structure, we expect to deploy up to $3.5 billion for disciplined M&A and opportunistic share repurchases over the plan period."
08:03 EDTXYLXylem reaffirms FY outlook at Investor & Analyst Day

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use